GoHealth (NASDAQ:GOCO) Trading Down 2.3% - Should You Sell?

Key Points

• GoHealth's shares fell 2.3% to $4.66, with trading volume significantly down 60% from the average session.
• Wall Street analysts show mixed opinions, with one brokerage downgrading GoHealth to a "sell" rating while another maintains an "outperform" rating, suggesting a consensus Moderate Buy with a price target of $12.00.
• GoHealth reported a quarterly earnings with an EPS of ($1.23), surpassing estimates, but revenue fell short of expectations at $94.05 million.

Shares of GoHealth, Inc. (NASDAQ:GOCO - Get Free Report) fell 2.3% during trading on Thursday . The company traded as low as $4.66 and last traded at $4.66. 16,998 shares were traded during mid-day trading, a decline of 60% from the average session volume of 42,374 shares. The stock had previously closed at $4.77.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GOCO. Wall Street Zen lowered shares of GoHealth from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Noble Financial reaffirmed an "outperform" rating on shares of GoHealth in a research report on Friday, August 8th. Finally, Royal Bank Of Canada cut their price target on shares of GoHealth from $18.00 to $12.00 and set a "sector perform" rating for the company in a research note on Thursday, August 28th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.00.

GoHealth Trading Down 2.3%

The stock has a market cap of $133.32 million, a price-to-earnings ratio of -1.29 and a beta of 1.62. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 2.64. The business's 50 day simple moving average is $5.24 and its 200 day simple moving average is $7.13.

GoHealth (NASDAQ:GOCO - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.23) EPS for the quarter, beating analysts' consensus estimates of ($2.60) by $1.37. The firm had revenue of $94.05 million during the quarter, compared to analysts' expectations of $119.76 million. GoHealth had a negative net margin of 3.21% and a negative return on equity of 8.74%. On average, research analysts expect that GoHealth, Inc. will post -5.5 EPS for the current fiscal year.

Hedge Funds Weigh In On GoHealth

Large investors have recently modified their holdings of the stock. FNY Investment Advisers LLC bought a new position in shares of GoHealth in the first quarter valued at about $31,000. N.E.W. Advisory Services LLC bought a new position in shares of GoHealth in the first quarter valued at about $45,000. American Century Companies Inc. bought a new position in shares of GoHealth in the second quarter valued at about $63,000. Bank of America Corp DE raised its position in shares of GoHealth by 22.8% in the fourth quarter. Bank of America Corp DE now owns 7,831 shares of the company's stock valued at $105,000 after purchasing an additional 1,452 shares during the period. Finally, Cubist Systematic Strategies LLC raised its position in shares of GoHealth by 297.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,915 shares of the company's stock valued at $134,000 after purchasing an additional 8,168 shares during the period. 24.21% of the stock is owned by institutional investors.

GoHealth Company Profile

GoHealth, Inc operates as a health insurance marketplace and Medicare-focused digital health company in the United States. The company operates a technology platform that leverages machine-learning algorithms of insurance behavioral data to optimize the process for helping individuals find the health insurance plan for their specific needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.